Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by JayjayUSA12007on Jun 01, 2018 10:12pm
140 Views
Post# 28114570

RE:RE:Why paying off EMD Sorono ?

RE:RE:Why paying off EMD Sorono ?
palinc2000 wrote:

Congrats for your calculation .... it shows you understand the maths
But I fail to see the pertinence of your conclusion....I think you mean to say that the contractual obligations  of 28.2 million $ is just an estimate and that increase Egrifta sales would have increased that amount.
Question#1
How do you know that the 28.2 million is an estimate and not a maximum?

I have been saying from the start that the prepayment of the Serono obligations is a zero sum operation,

So why is about 50% of the Financing being invested in a transaction which is not adding to profit?
This is why I think that getting rid of the First Lien on the assets was the primary reason and if I am right it means that something else is coming since the prepayment by itself is not based on economics

However the remaining 50% can indeed be invested in growth opportunities
So I am supportive of the mechanics of the financing ((conversion price .interest rate) but raise a big question mark for the use of 50% of the proceeds



Pretty good, palinc2000. No need to congrat me, BTW.
Read me recent post....

Bullboard Posts